3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Alcohol Drinking
11
Pancreatic Neoplasms
6
Neoplasms
5
Smoking Cessation
4
Pancreatic Cyst
4
Cancer Pain
4
Agnosia
4
Smoking
3
Pain
3
Depression
3
Prostatic Neoplasms
2
Postoperative Complications
2
Neoplasms, Cystic, Mucinous, and Serous
2
Multiple Endocrine Neoplasia Type 1
2
Lymphoma, Follicular
2
Lymphoma
2
Leukemia
2
Infections
2
Gliosarcoma
2
Glioblastoma
2
Condylomata Acuminata
2
Colorectal Neoplasms
2
Central Nervous System Neoplasms
2
Cardiovascular Diseases
2
Breast Neoplasms
2
Brain Neoplasms
2
Alcoholism
2
Wounds and Injuries
1
Warts
1
Waldenstrom Macroglobulinemia
1
Interventions
Trastuzumab
597
Paclitaxel
562
Cyclophosphamide
545
Docetaxel
479
Capecitabine
388
Letrozole
350
Fulvestrant
311
Doxorubicin
285
Carboplatin
277
Tamoxifen
257
Anastrozole
219
exemestane
211
Epirubicin
210
Radiotherapy
197
Bevacizumab
189
pertuzumab
177
Gemcitabine
163
Vinorelbine
162
pembrolizumab
161
Lapatinib
161
palbociclib
152
Exercise
132
Fluorouracil
118
Albumin-Bound Paclitaxel
116
eribulin
108
Magnetic Resonance Spectroscopy
108
130-nm albumin-bound paclitaxel
107
Everolimus
103
Taxes
96
Cisplatin
92
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Breast Neoplasms
×
Ethanol
×
Clear all
NCT04007549
2024-11-19
IBMC
Institut Bergonié
Phase NA
Withdrawn
NCT01698918
2023-05-03
BOLERO-4
Novartis
Phase 2
Completed
202 enrolled
19 charts